- Product Details
Keywords
- 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile
- 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
- adagrasib
Quick Details
- ProName: Adagrasib
- CasNo: 2326521-71-3
- Molecular Formula: C32H35ClFN7O2
- Appearance: white powder
- Application: Covalent inhibition of KRAS 12C with p...
- DeliveryTime: 2 months
- PackAge: fiber can
- Port: shanghai port
- ProductionCapacity: 100 Kilogram/Year
- Purity: 99%
- Storage: store at 2-8℃
- Transportation: air transport
- LimitNum: 100 Gram
- Related Substances: ≤0.1%
- Residue on Ignition: ≤0.1%
- Heavy Metal: ≤20ppm
- Valid Period: 2 years
Superiority
The quality of our products is guaranteed and the price is low!
Details
CAS number :2326521-71-3
English name :MRTX-849 English alias :Adagrasib; 2 - (4 - ((S) - 7 - (8 - chloronaphthalen - 1 - yl) - 2 - (((S) - 1 - methylpyrrolidin - 2 - yl) methoxy) - 5,6,7,8 - tetrahydropyrido pyrimidin - [3, 4 - d] 4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; MRTX-849; Adagrasib/MRTX-849; MRTX849(Adagrasib); AzvudineImpurity23; MRTX849; MRTX-Chemicalbook849; MRTX849; 4 - [7-8 - CHLORO - 1 - (NAPHTHALENYL) - 5,6,7,8 - TETRAHYDRO - 2 - [[(2 s) - 1 - METHYL - 2 - PYRR; 4 - [2 - PIPERAZINEACETONITRILE, 7-8 - CHLORO - 1 - (NAPHTHALENYL) - 5,6,7,8 - TETRAHYDRO - 2 - [[(2 s) - 1 - METHYL - 2 - PYRR; 4 - [2 - PIPERAZINEACETONITRILE, 7-8 - CHLORO - 1 - (NAPHTHALENYL) - 5, Chemicalbook6, 7, 8 - TETRAHYDRO - 2 - [[(2 s) - 1 - METHYL - 2 - PYRR
Molecular formula:
C32H35ClFN7O2
Molecular weight:
604.12
Boiling point 860.2±75.0 °C(Predicted)
Density 1.295± 0.06g /cm3(Predicted)
Storage conditions -20°C
Soluble in DMSO:1.0(Max Conc.mg /mL); 1.7(Max Conc.mM)
Acidity coefficient (pKa)9.31±0.40(Predicted)
Morphological crystalline solid
MRTX-849 is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRASG12C mutation who have previously received at least one systemic therapy.
Biological activity